Bright Light Exposure in Surgical Patients

Launched by UNIVERSITY OF COLORADO, DENVER · Jan 29, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of bright light therapy on patients undergoing heart surgery. The researchers believe that exposure to intense light before surgery can help stabilize certain important proteins in the body and reduce heart damage after the procedure. They also want to see if light therapy can improve blood vessel function, which is often impaired in critically ill patients. This is important because better vessel function can help prevent serious complications like strokes or heart attacks.

To participate in this trial, patients need to be between 18 and 90 years old and scheduled for a specific type of heart surgery. They should also have a normal heart rhythm at the time of surgery. If eligible, participants can expect to receive bright light therapy before their surgery, and the researchers will collect a small sample of heart tissue during the procedure for analysis. It’s worth noting that certain conditions, such as being pregnant or having severe neurological disorders, may exclude someone from joining the trial. Overall, this study aims to explore a new way to support heart health in critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing primary sternotomy cardiac surgery
• • Subjects in the range of 18 - 90 years old .
• • Patient need to be in sinus rhythm at the time of surgery.
• Exclusion Criteria:
• • patients \<18 or \>90 years old
• • participation in other clinical trials within the previous 30 days
• • pregnancy
• • neurological conditions that could impair weaning from ventilator support
• • significant CNS disorders or comorbid irreversible conditions with a six-month mortality rate more than 50 percent
• • prisoners, or subjects with altered capabilities to make decision will be enrolled
• • medical history of type 2 diabetes
• • patients with atrial fibrillation or use of class III anti-arhythmic drug
• • patients with a left ventricle ejection fraction \< 40%
• • patient in emergency condition